Tetra technologies awarded water treatme
๐
Article
๐
1998
๐
Elsevier Science
๐
English
โ 127 KB
receiving net proceeds of US$33 480 000. V1TEX is a leading developer of a broad portfolio of blood products and systems using its proprietary viral inactivation technologies. VITEX's technologies are intended to address the risk of viral contamination in blood products, including plasma, plasma der